Iradimed (NASDAQ:IRMD - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at Roth Mkm in a report issued on Monday, Benzinga reports. They presently have a $65.00 price objective on the medical equipment provider's stock. Roth Mkm's price objective would indicate a potential upside of 53.45% from the company's previous close.
Separately, Singular Research reissued a "buy" rating on shares of Iradimed in a report on Monday, April 1st.
Read Our Latest Stock Report on IRMD
Iradimed Price Performance
Shares of IRMD stock traded up $1.36 during midday trading on Monday, hitting $42.36. The company had a trading volume of 30,918 shares, compared to its average volume of 51,555. The stock has a market cap of $536.28 million, a price-to-earnings ratio of 31.19 and a beta of 0.82. The company's 50 day simple moving average is $43.11 and its 200 day simple moving average is $43.02. Iradimed has a 52-week low of $36.12 and a 52-week high of $51.04.
Iradimed (NASDAQ:IRMD - Get Free Report) last issued its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.36 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.01). Iradimed had a return on equity of 24.62% and a net margin of 26.22%. The company had revenue of $17.45 million for the quarter. Analysts anticipate that Iradimed will post 1.35 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Resource Consulting Group Inc. purchased a new stake in shares of Iradimed during the 4th quarter worth $4,889,000. RK Capital Management LLC increased its holdings in Iradimed by 13.2% during the 4th quarter. RK Capital Management LLC now owns 340,400 shares of the medical equipment provider's stock valued at $16,159,000 after acquiring an additional 39,600 shares in the last quarter. Bridge City Capital LLC acquired a new position in Iradimed during the third quarter worth about $1,250,000. Ballast Asset Management LP purchased a new stake in shares of Iradimed in the third quarter valued at about $1,113,000. Finally, Swiss National Bank acquired a new stake in shares of Iradimed in the third quarter valued at approximately $737,000. Institutional investors and hedge funds own 92.34% of the company's stock.
Iradimed Company Profile
(
Get Free Report)
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.
See Also
Before you consider Iradimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Iradimed wasn't on the list.
While Iradimed currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
